Arkgen Bioscions Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $6.54M

  • Investors
  • 15

Arkgen Bioscions General Information

Description

Developer of protein-based therapeutics designed for immuno-oncology purposes. The company's platform utilizes advanced biotechnology and a research and development framework to access cutting-edge treatments that target specific proteins, enabling the healthcare market to enhance immune response and offer potential improvements in patient outcomes for cancer therapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 402-4, B4, 582 Daedeok-daero
  • Okto Building, Yuseong-gu, Doryong-dong
  • Daejeon
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Number 402-4, B4, 582 Daedeok-daero
  • Okto Building, Yuseong-gu, Doryong-dong
  • Daejeon
  • South Korea
+82

Arkgen Bioscions Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arkgen Bioscions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 13-Jul-2026 $6.54M Completed Generating Revenue
3. Accelerator/Incubator 30-Nov-2023 Completed Generating Revenue
2. Seed Round 05-Jul-2023 $3.09M $3.09M Completed Generating Revenue
1. Accelerator/Incubator Completed Stealth
To view Arkgen Bioscions’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Arkgen Bioscions Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arkgen Bioscions Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Huons Global Corporation Minority
IBK Venture Investment Corporate Venture Capital Minority
IMM Investment Asset Manager Minority
Industrial Bank of Korea PE/Buyout Minority
Korea Credit Guarantee Fund Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Arkgen Bioscions Investments (1)

Arkgen Bioscions’s most recent deal was a Corporate Asset Purchase with LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform). The deal was made on 18-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform) 18-Nov-2024 Corporate Asset Purchase Buildings and Property
To view Arkgen Bioscions’s complete investments history, request access »

Arkgen Bioscions Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform) Seoul, South Korea

Arkgen Bioscions FAQs

  • When was Arkgen Bioscions founded?

    Arkgen Bioscions was founded in 2021.

  • Where is Arkgen Bioscions headquartered?

    Arkgen Bioscions is headquartered in Daejeon, South Korea.

  • What is the size of Arkgen Bioscions?

    Arkgen Bioscions has 12 total employees.

  • What industry is Arkgen Bioscions in?

    Arkgen Bioscions’s primary industry is Drug Discovery.

  • Is Arkgen Bioscions a private or public company?

    Arkgen Bioscions is a Private company.

  • What is Arkgen Bioscions’s current revenue?

    The current revenue for Arkgen Bioscions is .

  • How much funding has Arkgen Bioscions raised over time?

    Arkgen Bioscions has raised $9.6M.

  • Who are Arkgen Bioscions’s investors?

    Huons Global, IBK Venture Investment, IMM Investment, Industrial Bank of Korea, and Korea Credit Guarantee Fund are 5 of 15 investors who have invested in Arkgen Bioscions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process